#China #healthcare #Hangzhou #medical technology #Zylox-Tonbridge

Zylox-Tonbridge Achieves Significant Financial Milestone

On March 20, 2025, Zylox-Tonbridge Medical Technology Co., Ltd. shared its remarkable financial results for the year 2024. The company reported a total revenue of USD 109.4 million, showing a 48.3% increase compared to the previous year. Most notably, Zylox-Tonbridge has declared a net profit of over USD 14 million, representing a significant milestone as it is the company's first full-year profit since its inception.

Operational Success Amid Market Challenges

Despite operating in a dynamic and often challenging market environment, Zylox-Tonbridge capitalized on economies of scale. Its continuous revenue growth has allowed the company to transition into a new phase characterized by sustainable profitability. This success highlights Zylox-Tonbridge's robust capacity to develop a diverse range of product solutions while maintaining high quality and efficiency in operations.

Looking ahead, Zylox-Tonbridge remains steadfast in its mission to innovate for improved quality of life. The company's focus on advancing medical technology aims to enhance healthcare quality and secure long-term growth.

Advancements in Centralized Procurement

In 2024, Zylox-Tonbridge strategically engaged in centralized procurement. The company successfully participated in various bidding processes, leveraging its extensive portfolio of high-quality products. As a result, Zylox-Tonbridge's products saw increased penetration within hospitals, reinforcing its competitive edge in the market.

Among notable successes, the company's SilverSnake Intracranial Support Catheter emerged as a top contender, winning bidding opportunities in its category, while the ZYLOX Penguin Peripheral Venous Stent System became the sole domestic bidder winning a national-level tender for iliac vein indications. The company continued to establish a broad distribution network that now spans over 3,000 hospitals, fostering a stable foundation for ongoing growth.

Expanding Global Presence

The firm also dedicated substantial resources toward enhancing its overseas market presence. Currently, 20 of Zylox-Tonbridge's products are available in 24 countries and regions, including Germany, Italy, Argentina, Brazil, and the UAE. The company is actively conducting post-market clinical trials for innovative products like the Zenflex™ Peripheral Stent System and the ZENFLEX™ Pro Peripheral Drug-Eluting Stent System while participating in international academic conferences such as WLNC 2024, LINC 2024, and CIRSE 2024.

The international outreach translated to substantial revenue, contributing USD 3.2 million to the company’s earnings in 2024, reflecting an impressive four-year compound annual growth rate of 87%.

Pioneering Medical Innovations

Zylox-Tonbridge's commitment to innovation led to the launch of multiple groundbreaking products in 2024. The company has vigorously pursued technology intersections such as AI and healthcare to further enrich product offerings and service enhancements. The unveiling of the ZYLOX Penguin Peripheral Venous Stent System marked a significant advancement in addressing peripheral venous diseases, while the Kylin Flow Diverter and the ZYLOX Unicorn Suture-mediated Closure System have set new benchmarks in the medical device market.

Additionally, ZYLOX Pantheris™ and ZYLOX Tigereye ST™ catheters, now entering the special review process for innovative medical devices, showcase the company’s focus on next-generation imaging and diagnostics technologies aimed at refining vascular interventions.

Zylox-Tonbridge has built a diverse pipeline featuring 66 products, with 47 approved by NMPA and 8 having achieved EU CE marks, and several others released in international markets.

Commitment to Operational Excellence

Zylox-Tonbridge's growth trajectory continues to be reinforced by operational efficiencies. In 2024, the company effectively reduced its R&D, sales, and administrative expense ratios, marking a decrease of 20, 9, and 10 percentage points, respectively, relative to 2023. Investments in digital and automated production lines at its Hangzhou and Zhuhai bases have optimized lean processes and strengthened supply chain management.

Since the full commercialization campaign launched in late 2020, Zylox-Tonbridge's products have gained traction with medical professionals, with over 800,000 units utilized in clinical settings.

Moving into the future, Zylox-Tonbridge is committed to its 'Innovation for Quality Life' mantra, actively increasing investments to supply global patients with affordable and high-quality medical solutions, emphasizing user accessibility to advanced medical technologies, and thereby contributing to the healthcare sector’s evolution.